Eli Lilly (LLY 1.80%) might just be the hottest pharmaceutical company on the planet right now. The company is the developer of a number of blockbuster drugs including Verzenio, Trulicity, and Taltz.
Of course, I'd be remiss to not include the company's latest hits in weight loss. Lilly's diabetes and obesity care medications, Mounjaro and Zepbound, are currently fueling a new wave of growth for the pharma leader and I don't see that slowing down anytime soon.
But what if I told you that there's an entirely other reason to love Eli Lilly stock besides its highly successful medicine portfolio?
Below, I'll break down one under-the-radar reason to consider Lilly for your portfolio for the long haul. Passive income investors won't want to miss this one.
Did you know that Eli Lilly is a dividend stock?
With a dividend yield of roughly 0.60%, I'd understand if Lilly's dividend leaves you uninspired. However, I'd encourage investors to zoom out and think long-term here. Lilly has a long history of not only paying a dividend, but raising it.
Today, investors receive a quarterly dividend payment of $1.30 per share (or $5.20 annually).
LLY Dividend data by YCharts
From 2009 until 2014, Lilly's quarterly dividend payment stayed flat at $0.49 per share (or $1.96 annually). The table below illustrates changes to Lilly's annual dividend since 2015.
| Category | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Annual dividend per share | $2.00 | $2.04 | $2.08 | $2.25 | $2.58 | $2.96 | $3.40 | $3.92 | $4.52 |
| Growth (YOY) | 2% | 2% | 2% | 8% | 15% | 15% | 15% | 15% | 15% |
Data source: Eli Lilly. YOY = year over year.
As the figures above indicate, Lilly has not just maintained a dividend, but it's grown its payment by more significant magnitudes over time. Furthermore, the company tends to declare its dividend hikes around December.
Although I cannot say with 100% certainty if and when Lilly will raise its dividend again, I think there's a good chance the company will continue rewarding shareholders by either maintaining its current $5.20 annual dividend or perhaps announce yet another raise at the end of the year.
Image source: Getty Images.
Eli Lilly has been a tremendous long-term investment
Eli Lilly is much more than a growth stock; it's truly a prolific medicine company that's managed to positively impact several pockets of the healthcare realm for decades.
Since 1972, shares of Eli Lilly have generated a total returns north of 100,000%. Clearly, Lilly has been a consistent multibagger opportunity for patient investors.
While much of the stock appreciation can be attributed to Lilly's steadfast commitment to innovation -- underscored by meaningful research and development (R&D), which has allowed Lilly to continually enter emerging opportunities in healthcare -- reinvesting dividends and holding onto the stock has also proven to be a lucrative strategy to generate even more gains.
Right now, Lilly is in the early stages of disrupting the weight loss market, and the company just received clearance from the Food and Drug Administration (FDA) for its Alzheimer's candidate, donanemab. I see Lilly as a compelling long-term opportunity and very much see the rising dividend as a fringe benefit of owning the stock.
Considering management has raised the dividend each year for nearly a decade around December, now could be an interesting time to pounce on Lilly stock.
